The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa

Tembeka Sineke 1*†, Denise Evans 1†, Kathryn Schnippel 2, Heleen van Aswegen 3, Rebecca Berhanu 1,4, Nozipho Musakwa 1, Elisabet Lönnmark 5, Lawrence Long 1,4 and Sydney Rosen 1,4

Abstract

Background: Adverse events (AEs) are common during treatment of drug-resistant tuberculosis (DR-TB). Little is known about the health-related quality of life (HRQoL) of patients receiving treatment for DR-TB or the effect of AEs on HRQoL.

Methods: We conducted a cross-sectional study among adult patients with laboratory-confirmed rifampicin resistant tuberculosis (TB) on DR-TB treatment at a public-sector outpatient DR-TB clinic in Johannesburg, South Africa between 02/2015–01/2018. Data on HRQoL using the Medical Outcomes Short Form-36 (SF-36) questionnaire and self-reported AEs were collected by trained interviewers through face-to-face interviews. We report averages for the eight major domains and mental (MCS) and physical health (PCS) component summary scores, stratified by whether AEs were reported in the last four weeks. For comparative purposes, we enrolled two other patient groups and included data on a separate group of healthy adults.

Results: We enrolled 149 DR-TB patients (median age 36 years IQR 29–43, 55% male, 77.9% HIV-positive, 81% on ART, 61.8% on a standard long-course regimen and 44.3% on DR-TB treatment for less than 6 months). 58/149 (38.9%) patients reported a total of 122 AEs in the preceding 4 weeks, of these the most common were joint pain (n = 22), peripheral neuropathy (n = 16), hearing loss (n = 15), nausea and vomiting (n = 12) and dizziness or vertigo (n = 11). SF-36 domains and summary scores (MCS and PCS) were lower in those who reported an AE compared to those who did not, and both were lower than healthy adults. Compared to those who did not report an AE, patients who reported AEs were more likely to have a low MCS (aRR 2.24 95% CI 1.53–3.27) and PCS (aRR 1.52 95% CI 1.07–2.18) summary score. HRQoL was lower among those on DR-TB treatment for 6 months or less.

Conclusion: Results show that DR-TB had a substantial impact on patients’ quality of life, but that AEs during the early months on treatment may be responsible for reducing HRQoL even further. Our findings highlight the negative effects of injectable agents on HRQoL. Patients require an integrative patient-centered approach to deal with DR-TB and HIV and the potential overlapping toxicities which may be worsened by concurrent treatment.

Keywords: Health-related quality of life (HRQoL), HIV/AIDS, DR-TB, Adverse events, SF-36, Mental health component summary scores, Physical health component summary scores
Background

South Africa bears a disproportionate share of the world’s epidemic of drug-resistant tuberculosis (DR-TB) [1], with an estimated 15,986 laboratory-confirmed rifampicin-resistant tuberculosis and multi-drug resistant (RR/MDR-TB) cases reported in 2017. Of these, 10,259 (64.2%) started appropriate DR-TB treatment [1]. The treatment for RR/MDR-TB takes much longer and is more complex and often more toxic than the treatment used for drug-susceptible TB (DS-TB) and is comprised of agents that are associated with the occurrence of serious adverse events (AE) [2, 3]. AEs range from ones that temporarily reduce quality of life (e.g. abdominal pain, rash, nausea, vomiting) to those that cause long-term disability (e.g. irreversible hearing loss) or are potentially life threatening (e.g. renal failure, psychosis, seizures) [3–6]. Studies have shown that up to 64% of patients require discontinuation of one or more drugs from their DR-TB treatment due to severe AEs [5, 7–9], which are particularly common during the intensive phase of therapy [6]. AEs have been shown to affect treatment adherence and are associated with poorer treatment outcomes, more specifically retention in care [2].

Tuberculosis has substantially adverse impacts on patient’s quality of life [10, 11]. Although the severity and extent of AEs relating to DR-TB treatment are well documented, little is known about health-related quality of life (HRQoL) of patients receiving treatment for DR-TB or the effect of AEs on HRQoL [9, 10, 12]. The evidence that is available shows that some AEs severely impact and lower patients’ HRQoL [10, 13–15] and that there is an association between quality of life and adherence to therapeutic recommendations (e.g. appointment keeping or adherence to medication) [2, 16].

Understanding patient experiences of AEs and how AEs affect their quality of life and their perception of care are important in creating treatment guidelines that better serve patients. Providing care that is responsive to the individual patient (i.e. an integrative patient-centered approach aimed at alleviating illness, suffering and death of individuals due to TB) may improve treatment outcomes and contribute towards meeting the United Nations Sustainable Development Goal 3 (SDG 3) target and support the End TB strategy of the World Health Organization (WHO) [17, 18].

To date, no published study has evaluated the association between the reporting of AEs and patients’ HRQoL scores during MDR-TB treatment, in a setting with high rates of HIV co-infection and antiretroviral therapy (ART) coverage. In this cross-sectional study, we describe the HRQoL of DR-TB patients in Johannesburg, South Africa, stratified by self-reported AEs in the past 4 weeks. We also present HRQoL of DR-TB patients disaggregated by (i) duration of DR-TB treatment, (ii) type of DR-TB regimen and (iii) HIV status. We compare the SF-36 domains to HIV positive patients who were on ART for at least 6 months either with or without DS-TB (within the past 12 months) and healthy adults (no self-reported chronic or infectious diseases; i.e. HIV and TB uninfected).

Over the course of our study, there have been substantial changes to the treatment guidelines for both DR-TB and HIV/AIDS in South Africa (Fig. 1). While South Africa has opted for all oral regimens for RR/MDR-TB by replacing injectables with bedaquiline and linezolid [19], the WHO has taken a more conservative approach and proposed two options: an all-oral, long, 18–20-month regimen or a shorter, injectable-based, 9–12-month regimen [20]. These changes are likely to affect AE profiles, but additional evidence on the negative impact of injectable agents on HRQoL may help countries decide to adopt oral or injectable regimens for RR/MDR-TB treatment in their national programs.

Methods

We conducted a cross-sectional study among adult patients on DR-TB treatment at a public sector, decentralized outpatient treatment site in Johannesburg, South Africa. For this cross-sectional study, a census of patients from a larger on-going, prospective observational cohort study of RR/MDR-TB patients at the same facility (Wits HREC protocol M130205) who met the eligibility criteria were selected. This cohort has been described in detail elsewhere [21].

To better understand the HRQoL scales we enrolled two comparison groups from two primary health facilities (PHCs) and a hospital-based HIV clinic in Johannesburg, South Africa. The facilities were purposely selected because they treat specific patient types (e.g. HIV-positive patients on ART with or without DS-TB) in whom we were interested and because they are located in the same catchment area (within < 5 km of one another; in City of Johannesburg Region G) as the decentralized outpatient DR-TB treatment facility. We also included data from a published study on a separate group of healthy adults [22], for comparative purposes.

Study population

To describe the effect of AEs on HRQoL, we included adults (≥18 years) with documented laboratory confirmed RR/MDR-TB, who were enrolled in the larger prospective cohort study after 1 March 2013 and returned to the clinic for DR-TB treatment between 1 February 2015 and 1 January 2018. Interviewers reviewed the DR-TB register at the healthcare facility to identify potential participants and recorded their upcoming visit date. When patients returned to the clinic interviewers identified and approached patients, informed them of the study, confirmed eligibility and obtained written informed consent.
For the comparison groups, we enrolled a sequential sample of patients as they presented at the facilities between January 2016 and January 2018. We included adult patients (≥18 years) who were HIV-positive and on ART for at least 6 months, either with or without DS-TB (within the past 12 months).

**Treatment regimens**

There were several RR/MDR-TB treatment regimen and diagnostic guidelines in effect over the course of this study (Fig. 1). In 2011, South Africa introduced Xpert MTB/RIF for the diagnosis of TB and rifampicin (RIF) resistance. At the same time the National TB program adopted a policy of decentralized, outpatient treatment for DR-TB [23]. In 2013, the standard long-course RR/MDR-TB regimen remained in use. This consisted of 6 months of injectable kanamycin and 18–24 months of oral moxifloxacin, ethionamide, terizidone, and pyrazinamide. In October 2014, the South African Medicines Control Council regulatory authority approved the use of bedaquiline (BDQ) for compassionate use in MDR-TB. In March 2015, BDQ became available in the South African National TB Programme (NTP) [24]. BDQ was introduced as a substitute for kanamycin in patients with either contraindication to receiving an aminoglycoside (baseline hearing loss or renal dysfunction) or for those who developed an AE to standard treatment. In addition, patients with MDR-TB and both the inhA and katG isoniazid drug resistance mutations were also given BDQ in an injection-free regimen [25]. In May 2016, the SA NTP implemented short course RR/MDR-TB treatment which consisted of 6 months intensive phase of kanamycin, moxifloxacin, ethionamide, clofazimine, pyrazinamide, and high-dose isoniazid followed by 5 months of moxifloxacin, clofazimine, pyrazinamide, and ethambutol.

For HIV and ART, South Africa began initiating patients on a once-daily, single tablet fixed dose combination of tenofovir, emtricitabine and efavirenz after April 2013. Tenofovir replaced stavudine, a drug known to cause serious side effects, in a triple combination regimen [26]. In September 2016, South Africa implemented Universal Test & Treat (UTT) guidelines, eliminating the CD4 count < 500 cells/mm³ threshold for ART initiation and then in July 2017, in line with WHO recommendations, adopted same day ART initiation for clinically stable patients [27].

**Data collection**

Data were collected by trained interviewers through face-to-face interviews using the Medical Outcomes Short Form-36 (SF-36) [28–30] (https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html) questionnaire for HRQoL and the Patient-Reported Adverse Drug Event Questionnaire which is a validated tool to assess patient-reported AE [11, 31]. The SF-36 questionnaire has been validated for consistency and reliability in different settings for a multitude of health conditions including TB [12, 32, 33]. Among those who reported hearing loss, we used the Hearing Handicap Inventory for the Elderly Screening Version (HHIE-S) to assess how individuals perceived the social and emotional effects of hearing loss (i.e. no, mild-moderate or severe handicap) [11, 12, 31–34]. For those with hearing loss, persons accompanying the patient to the clinic (e.g. family member) helped to interpret the questions for the patient.

**Sources of data**

All data collected during the interviews were collected on paper forms and later captured into REDCap [35] by study staff for data cleaning and analysis. Patient demographics, including gender, age, education, HIV status,
DR-TB treatment start date, treatment regimen, and disease classification were obtained from the facility’s electronic patient record database. Survey responses were linked to patient demographics using the unique study ID which was assigned at enrolment in the prospective observational cohort study and a single analytic dataset was created.

For the comparison groups, SF-36 data were captured directly into REDCap using a Samsung Galaxy tablet. Interviewers also collected basic demographic and clinical information from the patient’s file. Data from a published report, which enrolled 40 healthy adults in Johannesburg (i.e. also in City of Johannesburg Region G), were used as a separate reference group [22].

Study variables
For the analysis, we scored the SF-36 according to the scoring guideline for this instrument [28–30] (Additional file 1: Table S1). The eight domains (i.e. physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions) were aggregated into two summary measures: the physical (PCS) and mental (MCS) component summary scores.

The Patient-Reported Adverse Drug Event Questionnaire [11, 31] lists over 400 possible symptoms that a patient could experience in the past 4 weeks, many of which are not related to DR-TB treatment (e.g. greasy skin, blushing, sneezing, goosebumps etc.). For the analysis, all symptoms or complaints reported were reviewed by a clinician (RB) and those unrelated to DR-TB treatment were excluded. The remaining symptoms were grouped into common AEs associated with RR/MDR-TB medication (See Additional file 3: Table S3 for events included). Patients were classified as having an AE (any grade) associated with RR/MDR-TB medication if they reported any of the included symptoms/AEs to the study interviewer in the past 4 weeks.

Patient characteristics recorded at treatment initiation included gender (male, female), age (18–35, ≥35 years), education (secondary school and higher, primary school and less) and employment status. Employment was classified as either unemployed (including students or retired) or employed (including self-employed or casual employment). We classified the resistance pattern according to the diagnostic method used: rifampicin (rif) resistant by Xpert MTB/RIF (Cepheid, USA); RR-TB diagnosed by Xpert MTB/RIF with unknown or pending sensitivity to isoniazid or second-line TB drugs), MDR-TB (rif and isoniazid resistant), or rif mono-resistant (mono- or poly-resistant resistance to rif alone or rif plus another first-line drug other than isoniazid, confirmed by line probe assay or DST).

HIV status was obtained from the facility’s electronic patient record database and categorized as HIV-negative, HIV-positive on ART, HIV-positive not on ART, or HIV status unknown. Additional patient information collected at treatment initiation included diabetes (no, yes, missing/unknown), weight (<50 kg, ≥50 kg, missing), referring facility (outpatient, inpatient), patient category (new, previously treated), TB type (pulmonary, extra pulmonary) and smear microscopy (negative, positive, unknown). For defining anaemia, haemoglobin (Hb) was adjusted downward by 0.65 g/dL to account for elevation above sea level in Johannesburg [36]. Anaemia was categorized according to WHO guidelines as none (Hb ≥12 g/dL for non-pregnant women and Hb ≥13 g/dL for men), mild (Hb 11–11.9 g/dL for non-pregnant women and 11–12.9 g/dL for men), moderate (8–10.9 g/dL) and severe (Hb < 8 g/dL) [37].

Duration of ART and duration of DR-TB treatment were calculated from the treatment start date until the date of the interview, and were categorized as ≤6 vs. > 6 months. DR-TB treatment was categorized as either currently (i.e. date of the interview) receiving a standard or individualized (i.e. BDQ substituted for kanamycin) long- or short-course regimen. Patients who were categorized as being on an injection-free, BDQ-containing regimen, were either started on BDQ at baseline or were switched to BDQ due to an incident AE such as hearing loss or renal failure.

Statistical analysis
The primary outcomes of the analysis were low MCS or low PCS summary score which were determined using the median as a cut-off. Patients with a norm-based MCS or PCS summary score below the median cut-off were defined as having a low MCS or PCS summary score while patients with a summary score above or equal to the median cut-off were defined as having a normal-high MCS or PCS summary score.

Patient demographic and clinical characteristics at the start of DR-TB treatment were summarized using frequencies for categorical variables, means with standard deviation for normally distributed data or median and interquartile range (IQR) for not normally distributed data. We present patient demographics and clinical characteristics, stratified by whether the patients reported an AE associated with DR-TB treatment in the past 4 weeks. We present the mean, standard deviation, and Cronbach’s alpha for the eight domains (normal additive approach and norm-based approach) and the MCS and PCS summary scores, again stratified by whether the patients reported an AE in the past 4 weeks or not. For reliability, a Cronbach’ alpha value of > 0.80 was used to define good internal consistency of the SF-36 domains (Additional file 1: Table S1). To compare domains and summary scores...
for those who reported an AE versus those who did not, we used Wilcoxon rank sum or Kruskal-Wallis test for non-parametric data and the student t test for parametric or normally distributed data. We further stratified the summary scores by HIV status, duration of DR-TB treatment, and DR-TB regimen and present this alongside the summary scores for the comparison groups.

We identified patient characteristics associated with a low MCS and low PCS summary score respectively using a Poisson regression model to estimate the relative risk (RR) and 95% confidence interval. Variables in the univariate model that were significant at the 0.2 level along with variables known to be associated with the outcome of interest (e.g. age, gender, resistance pattern etc.) and potential confounders (i.e. variable changes the estimate by > 10%) were included in the multivariate regression model. The univariate and multivariate (adjusted) results are presented.

All analyses were carried out using STATA version 13 (STATA Corp, Texas, USA) and SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). This study and the analysis of anonymized data was approved by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (Wits HREC M141188). All participants provided written informed consent to participate in the study.

Results

Demographic and clinical characteristics

A total of 149 DR-TB patients were enrolled (Table 1). Patients had a median age of 36 years (IQR 29–43), 55.0% were male, and 42.3% were employed. Close to half (45.0%) of patients were classified as RIF mono-resistant (isoniazid sensitive), 25.5% had RIF resistance diagnosed by Xpert MTB/RIF with no further susceptibility testing and the remaining 21.5% were classified as MDR-TB. More than half (55.7%) of the patients had been on DR-TB treatment for more than 6 months. The majority (77.9%) were HIV positive; among these 81% were on ART, with 71.3% on ART for more than 6 months.

Overall, 38.9% (58/149) of patients self-reported to the interviewer a total of 122 AEs in the preceding 4 weeks, of which joint pain (n = 22), peripheral neuropathy (n = 16), hearing loss (n = 15), nausea and vomiting (n = 12), and dizziness or vertigo (n = 11) were the most common (Additional file 2: Table S2). Baseline characteristics of those who reported an AE versus those who did not were largely similar, though patients who reported an AE were more likely to have moderate or severe anemia (from laboratory results) (<11 g/dL vs. ≥12 g/dL; RR 1.78 95% CI 1.03–3.08) and were less likely to have more than a secondary school education (RR 0.56 95% CI 0.36–0.89) (Table 1).

For the comparison groups, we enrolled 18 patients who were HIV-positive on ART with DS-TB (median age 37 IQR 32–47; 44.4% male) and 50 patients who were HIV positive on ART (no TB) (median age 44 IQR 35–48; 40.0% male). For the published (healthy) comparison group, the mean age of this group was 29.5 (SD ±8.5) years with 39 males and one female [22].

Comparison of SF-36 scores and MCS and PCS component summary scores

Patients on DR-TB treatment who reported an AE had lower domains compared to patients who did not. Physical, emotional and social function were noticeably reduced among patients who reported an AE compared to those who did not. When comparing the MCS and PCS summary score, patients who reported an AE had lower summary scores than those who did not (MCS 32.1 vs. 42.2; PCS 46.5 vs. 52.8). Results were consistent across both the normal additive approach (not standardized) and the norm-based approach (standardized) (Table 2).

For all DR-TB patients, those who reported an AE and those who did not, the MCS was lower than the PCS (Table 3). DR-TB patients co-infected with HIV, but not on ART, had a lower MCS and PCS summary score than did co-infected patients who were on ART or patients who were HIV negative (MCS 34.5 vs. 38.7 or 41.4; PCS 46.7 vs. 51.2 or 50.9). DR-TB patients who had been on treatment for 6 months or less had a lower MCS and PCS summary score than patients who had been on treatment for more than 6 months (MCS 31.9 vs. 42.9; PCS 48.5 vs. 52.6).

Among HIV-positive patients on ART, DR-TB patients had a lower MCS than did those with DS-TB and those without TB (38.7 vs. 44.4 and 43.3) while both DR-TB and DS-TB patients had a lower PCS summary score than patients without TB (51.2 and 48.5 vs. 54.8) (Table 3). From published data, healthy adults in Johannesburg have a MCS and PCS summary score of 50.3 and 57.6, respectively (Additional file 3: Table S3) [22].

Adverse events and HRQoL by DR-TB regimen

Two-thirds of patients (61.8%) were on a standard long-course regimen, 10.1% were on a standard short-course regimen, and 28.1% had either switched to (n = 35/42) or initiated on an injection-free regimen (n = 7/42) (Table 1). Median time on BDQ at time of interview for those on BDQ was 3.1 months (IQR 0.7–6.3). A higher proportion of patients on a standard regimen (long- or short-course with injectables) experienced AEs than those on an individualized regimen (injection-free, BDQ-containing regimen) (40.2% vs. 34.4%). Patients on an individualized regimen were less likely to report an AE in the past 4 weeks, however the estimate lacked precision possibly because the numbers within each strata were quite small (RR 0.86 95% CI 0.51–1.45). Of the 15 patients that experienced hearing loss, two thirds were on a standard long-course regimen and the remaining one third were on an individualized long-course regimen (Additional file 2: Table S2). The MCS and PCS summary scores were similar among patients on a standard (i.e. containing an
| Table 1 Characteristics of patients by experience with adverse event during DR-TB treatment (n = 149) | Adverse event not reported (n = 91) | Patient-reported adverse event (n = 58) | Total (n = 149) |
| --- | --- | --- | --- |
| **Sex** | | | |
| Male | 47 (51.6%) | 35 (60.3%) | 82 (55.0%) |
| Female | 44 (48.4%) | 23 (39.7%) | 67 (45.0%) |
| **Age at treatment initiation (years)** | | | |
| Median (IQR) | 36 (29–44) | 35 (29–42) | 36 (29–43) |
| 18–35 | 45 (49.5%) | 29 (50%) | 74 (49.7%) |
| ≥ 35 | 46 (50.5%) | 29 (50%) | 75 (50.3%) |
| **Education** | | | |
| Secondary school and higher | 86 (94.5%) | 49 (84.5%) | 135 (90.6%) |
| Primary school or less | 5 (5.5%) | 9 (15.5%) | 14 (9.4%) |
| **Employment Status** | | | |
| Unemployed | 47 (51.6%) | 38 (65.5%) | 85 (57.0%) |
| Employed | 43 (47.3%) | 20 (34.5%) | 63 (42.3%) |
| Missing/unknown | 1 (1.1%) | 0 (0%) | 1 (0.7%) |
| **Resistance Pattern** | | | |
| MDR-TB (RIF and INH resistant) | 22 (24.2%) | 10 (17.2%) | 32 (21.5%) |
| RIF resistant by Xpert MTB/RIF | 22 (24.2%) | 16 (27.6%) | 38 (25.5%) |
| RIF mono-resistant (INH sensitive) | 39 (42.9%) | 28 (48.3%) | 67 (45.0%) |
| Missing | 8 (8.8%) | 4 (6.9%) | 12 (8.1%) |
| **HIV Status** | | | |
| HIV negative | 18 (19.8%) | 9 (15.5%) | 27 (18.1%) |
| HIV positive | 69 (75.8%) | 47 (81.0%) | 116 (77.9%) |
| HIV positive and on ART | 60 (87.0%) | 34 (72.3%) | 94 (81.0%) |
| HIV positive not on ART | 9 (13.0%) | 13 (27.7%) | 22 (19.0%) |
| Unknown | 4 (4.4%) | 2 (3.5%) | 6 (4.0%) |
| **Baseline CD4 (cells/mm$^3$)$^3$|$^4$** | | | |
| < 50 | 23 (31.5%) | 9 (18.4%) | 32 (26.2%) |
| 51–250 | 21 (27.8%) | 22 (44.9%) | 43 (35.3%) |
| > 250 | 22 (30.1%) | 14 (28.6%) | 36 (29.5%) |
| Missing | 7 (69.6%) | 4 (8.2%) | 11 (9.0%) |
| **DR-TB regimen** | | | |
| Standard long-course$^a$ | 61 (67.0%) | 31 (53.4%) | 92 (61.8%) |
| Individualized long-course$^b$ | 17 (18.7%) | 16 (27.6%) | 33 (22.1%) |
| Standard short-course$^c$ | 9 (9.9%) | 6 (10.3%) | 15 (10.1%) |
| Individualized short-course$^d$ | 4 (4.4%) | 5 (8.6%) | 9 (6.0%) |
| **Duration of DR-TB treatment (months)** | | | |
| ≤ 6 months | 37 (40.7%) | 29 (50.0%) | 66 (44.3%) |
| > 6 months | 54 (59.3%) | 29 (50.0%) | 83 (55.7%) |
| **Duration of ART (months)$^6$** | | | |
| ≤ 6 months | 9 (15.0%) | 5 (14.7%) | 14 (14.9%) |
| > 6 months | 44 (73.3%) | 23 (67.6%) | 67 (71.3%) |
| Missing | 7 (11.7%) | 6 (17.6%) | 13 (13.8%) |
| **Diabetes** | | | |
injectable agent; e.g. kanamycin) or an individualized regimen (i.e. injection-free regimen) (MCS 37.9 vs. 39.3; PCS 51.1 vs. 48.7). However, all patients that reported an AE, whether on a standard or individualized regimen, had a lower MCS and PCS than patients that did not report an AE (Table 3).

Factors associated with low MCS or PCS component summary scores

Among DR-TB patients, we identified factors associated with having a low MCS score, as shown in Table 4. From the multivariate regression, DR-TB patients who reported an AE (aRR 2.24 95% CI 1.53–3.27) and those on DR-TB treatment for less than 6 months (≤6 vs. > 6 months; aRR 2.27 95% CI 1.53–3.35) were more likely to have a low MCS summary score. After adjusting for patient-reported AE, gender, age, resistance pattern and duration of DR-TB treatment, patients who were on a standard long- or short-course DR-TB regimen were more likely to have a low MCS summary score than those who either switched to or initiated on an injection-free regimen (aRR 1.49 95% CI 1.00–2.24).

We also identified factors that were associated with having a low PCS summary score Table 4. In the final
adusted multivariate regression both patient-reported AE (aRR 1.52 95% CI 1.07–2.18) and being on DR-TB treatment for less than 6 months (≤6 vs. > 6 months; aRR 1.70 95% CI 1.11–2.61) were associated with having a low PCS summary score.

**Discussion**

Although other studies have reported that AEs reduce the overall quality of life of patients [38, 39], this is one of the largest studies to describe the impact of AEs on HRQoL among patients receiving treatment for DR-TB. Close to 40% of patients reported recently experiencing an AE, with joint pain, peripheral neuropathy, and hearing loss the most common [40]. In this cross-sectional study, we found that HRQoL, more specifically mental health and wellbeing, were lower among DR-TB patients who self-reported experiencing an AE. Not surprisingly, all eight domains and both summary scales (MCS and PCS) on the SF-36 were lower in patients receiving treatment for DR-TB compared to healthy adults.

In a context where 77.9% of patients are also infected with HIV, patients initiating ART are more likely to experience an AE in the first six month of DR-TB treatment [6]. We found that HRQoL was influenced by duration of treatment. Patients in the intensive phase (first 6 months) of DR-TB therapy were more likely to have a low MCS and PCS. Unexpectedly, just over half of the patients who reported AEs had been receiving DR-TB treatment for more than 6 months. This could signify that either the AEs in the latter portion of DR-TB treatment are not as severe as those in the intensive phase and hence have lesser effect on MCS and PCS, or that these are persistent AEs that are either better tolerated or better managed than they had been during the intensive phase of treatment.

The role of DR-TB in determining HRQoL of HIV co-infected patients remains unclear. When limiting our comparison to HIV-positive patients on ART, we discerned a lower MCS summary score among co-infected patients receiving treatment for DR-TB compared to patients with DS-TB or those without TB. Contrary to other reports we found that the MCS summary score was similar among HIV co-infected patients with DS-TB and those with HIV alone, possibly because all of the patients were receiving ART [41].

HIV co-infected patients receiving treatment for DR-TB, but not on ART, had a low MCS and PCS summary score compared to patients who were on ART. This is consistent with other reports demonstrating an improved quality of life following the start of ART [42]. Co-infected patients

### Table 2 Comparison of SF-36 health domain scales (normal and norm-based) between DR-TB patients who reported an adverse event in the last four weeks and those who did not (n = 149)

| SF-36 scalea (Normal scale) | Items | Mean | SD  | Alpha* | Mean | SD  | Alpha* | P value** |
|-----------------------------|-------|------|-----|--------|------|-----|--------|----------|
| Physical functioning        | 10    | 89.0 | 16.9| 0.910  | 73.0 | 24.8| 0.869  | 0.0001   |
| Role functioning/physical   | 4     | 68.7 | 43.2| 0.906  | 29.7 | 43.3| 0.849  | 0.0001   |
| Role functioning/emotional  | 3     | 64.8 | 46.7| 0.909  | 22.9 | 39.1| 0.866  | 0.0001   |
| Energy/fatigue              | 4     | 58.3 | 16.3| 0.903  | 48.3 | 17.1| 0.861  | 0.006    |
| Emotional well-being        | 5     | 65.3 | 17.8| 0.902  | 54.8 | 17.1| 0.851  | 0.005    |
| Social functioning          | 2     | 78.6 | 22.8| 0.908  | 59.5 | 16.6| 0.859  | < 0.0001 |
| Pain                        | 2     | 78.5 | 20.9| 0.906  | 63.4 | 12.0| 0.86   | 0.0001   |
| General health              | 5     | 66.6 | 15.1| 0.914  | 59.3 | 13.8| 0.869  | 0.003    |

| SF-36 scalea (Norm-based scale) | Items | Mean | SD  | Alpha* | Mean | SD  | Alpha* | P value** |
|--------------------------------|-------|------|-----|--------|------|-----|--------|----------|
| Physical functioning           | 10    | 52.4 | 7.1 | 0.911  | 45.7 | 14.9| 0.869  | 0.0001   |
| Role functioning/physical      | 4     | 44.6 | 16.9| 0.907  | 29.3 | 17.7| 0.849  | 0.0001   |
| Role functioning/emotional     | 3     | 39.4 | 21.8| 0.91   | 19.9 | 18.2| 0.866  | 0.0001   |
| Energy/fatigue                 | 4     | 50.0 | 8.1 | 0.904  | 44.9 | 8.5 | 0.861  | 0.0005   |
| Emotional well-being           | 5     | 44.5 | 10.0| 0.903  | 38.6 | 8.6 | 0.851  | 0.007    |
| Social functioning             | 2     | 47.5 | 9.9 | 0.909  | 39.2 | 8.1 | 0.859  | 0.0001   |
| Pain                           | 2     | 53.0 | 8.8 | 0.907  | 46.2 | 10.6| 0.86   | 0.0001   |
| General health                 | 5     | 48.0 | 7.2 | 0.914  | 44.5 | 6.6 | 0.869  | 0.003    |
| Mental health component summary (MCS) | 42.2 | 13.0 | n/a | 32.1 | 9.9 | n/a | < 0.001 |
| Physical health component summary (PCS) | 52.8 | 8.2 | n/a | 46.5 | 9.1 | n/a | < 0.0001 |

*a using the 36-item Medical Outcomes Short Form Health Survey (SF-36)  
*bFor the Alpha, Cronbach’s alpha value of >0.80 was used to define good internal consistency of the SF-36 domains  
**For the P value, this was to indicate the difference between means for patients with AE vs those without. 0.05 was a cutoff for significance.
(DR- and DS-TB) had a low PCS summary score than those without TB, highlighting the need for strategies to incorporate social-psychological support and rehabilitation therapy to improve HRQoL. Some AEs (e.g. dizziness or vertigo, hearing loss and joint pain) are more prevalent in DR-TB patients co-infected with HIV [6], and those newly initiating ART. The persistence of AEs in HIV co-infected patients has been described [43] and may also possibly explain why patients continue to experience AEs throughout the course of DR-TB therapy.

In our study we found that in most instances the MCS was lower than the PCS summary score. While this may reflect the positive effect of TB treatment on improving patients’ quality of life, as physical health tends to recover more quickly than mental well-being [12], it may

| SF-36 scale | Mental component summary (MCS) | Physical component summary (PCS) |
|------------|-------------------------------|---------------------------------|
|            | Mean  SD                      | Mean  SD                        |
| DR-TB (all patients; n = 149) | 38.3 12.9                      | 50.4 9.1                        |
| Patient-reported adverse event |                              |                                 |
| No adverse event                  | 42.2 13.0                      | 52.8 8.2                        |
| Patient-reported adverse event    | 32.1 9.9                       | 46.5 9.1                        |
| HIV status                         |                                 |                                 |
| HIV negative (n = 27)             | 41.4 11.6                      | 50.9 8.7                        |
| HIV positive on ART (n = 94)      | 38.7 12.9                      | 51.2 8.5                        |
| HIV positive not on ART (n = 22)  | 34.5 13.9                      | 46.7 10.7                       |
| HIV status unknown (n = 6)        | 32.7 12.5                      | 49.0 11.6                       |
| Duration of DR-TB treatment       |                                 |                                 |
| ≤ 6 months (n = 66)               | 31.9 11.3                      | 48.5 9.9                        |
| > 6 months (n = 83)               | 42.9 12.0                      | 52.6 8.0                        |
| DR-TB regimen                      |                                 |                                 |
| Standard regimen (long- and short-course) (n = 107) | 37.9 13.4                      | 51.1 8.9                        |
| Did not report an AE              | 41.4 13.6                      | 53.2 8.2                        |
| Self-reported AE                  | 31.4 10.4                      | 47.1 8.8                        |
| Individualized regimen (long- and short-course) (n = 42) | 39.3 11.6                      | 48.7 9.4                        |
| Did not report an AE              | 45.1 10.8                      | 51.7 8.3                        |
| Self-reported AE                  | 33.4 9.3                       | 45.6 9.7                        |
| Comparison groups                 |                                 |                                 |
| HIV positive on ART with DS-TB (n = 18) | 44.4 15.7                      | 48.5 9.6                        |
| HIV positive on ART no TB (n = 50) | 43.3 11.5                      | 54.8 7.3                        |
| Healthy Adultsa (n = 40)          | 50.3 10.3                      | 57.6 5.1                        |

| *From published data (van Aswegen et al., 2011) |
| *Using the 36-Item Medical Outcomes Short Form Health Survey (SF-36) |

In its recommendation, the WHO argued that evidence is currently lacking for an all-oral short-course regimen (i.e. bedaquiline, linezolid or delamanid replacing the injectable agent) as clinical trial data is not yet available. However, there is growing pressure for programs to eliminate injectable regimens [44], given the mounting evidence for the safety and efficacy of bedaquiline from observational studies [25] coupled with the known harm caused by injectable agents [6]. Our study contributes to the body of evidence demonstrating the negative impact of injectable agents on HRQoL. These negative effects of injectable agents on HRQoL, adherence and willingness to remain engaged in care need to be taken into account as countries decide to adopt oral or injectable regimens for RR/MDR-TB treatment in their national programs.
|                         | Mental component summary score | Physical component summary score |
|-------------------------|--------------------------------|--------------------------------|
|                         | N, % (n = 74)      Crude RR (95% CI) Adjusted RR (95% CI) | N, % (n = 75)      Crude RR (95% CI) Adjusted RR (95% CI) |
| **Adverse event**       |                                |                                |
| Adverse event not reported | 31/91 (34.1%)     1.00 1.00       | 35/91 (38.5%)     1.00 1.00       |
| Adverse event reported  | 43/58 (74.1%)     2.18 (1.57–3.01) 2.24 (1.53–3.27) | 40/58 (69.0%)     1.79 (1.31–2.45) 1.52 (1.07–2.18) |
| **Sex**                 |                                |                                |
| Male                    | 39/82 (47.6%)     1.00 1.00       | 41/82 (46.1%)     1.00 1.00       |
| Female                  | 35/67 (52.2%)     1.10 (0.79–1.52) 1.23 (0.81–1.84) | 34/67 (54.8%)     1.01 (0.74–1.40) 1.10 (0.71–1.68) |
| **Age at treatment initiation (years)** |                                |                                |
| 18–35                   | 39/74 (52.7%)     1.00 1.00       | 37/74 (50.0%)     1.00 1.00       |
| > 35+                   | 35/75 (46.7%)     0.89 (0.64–1.23) 0.91 (0.62–1.34) | 38/75 (50.7%)     1.01 (0.74–1.40) 0.86 (0.56–1.31) |
| **Education**           |                                |                                |
| Secondary school and higher | 67/135 (49.6%)  1.00                | 71/135 (52.6%)  1.00                |
| Primary school or less  | 7/14 (50.0%)     1.01 (0.58–1.75)  | 4/14 (28.6%)     0.54 (0.23–1.27)  |
| **Employment Status**   |                                |                                |
| Unemployed              | 45/85 (52.9%)     1.00                | 45/85 (52.9%)  1.00                |
| Employed                | 28/63 (44.4%)     0.84 (0.60–1.18)  | 29/63 (44.4%)  0.87 (0.62–1.22)  |
| **Resistance Pattern**  |                                |                                |
| RIF resistant by Xpert MTB/RIF | 21/38 (55.2%)  1.00                | 21/38 (55.2%)  1.00                |
| RIF mono-resistant (INH sensitive) | 30/67 (44.8%)  0.81 (0.55–1.20) 0.89 (0.55–1.45) | 29/67 (43.3%)  0.78 (0.53–1.17) 0.88 (0.55–1.41) |
| MDR-TB (RIF and INH resistant) | 14/32 (43.8%)  0.79 (0.49–1.29) 1.09 (0.67–1.78) | 16/32 (50.0%)  0.90 (0.58–1.42) 1.15 (0.66–1.99) |
| Missing                 | 9/12 (75.0%)     1.36 (0.88–2.09) 0.98 (0.59–1.64) | 9/12 (75.0%)     1.36 (0.88–2.09) 1.26 (0.81–1.95) |
| **HIV Status**          |                                |                                |
| HIV negative            | 11/27 (40.7%)     1.00                | 13/27 (48.1%)  1.00                |
| HIV positive and on ART | 45/94 (47.9%)     1.18 (0.71–1.94)  | 44/94 (46.8%)  0.97 (0.62–1.52)  |
| HIV positive not on ART | 14/22 (63.6%)     1.56 (0.90–2.72)  | 15/22 (68.2%)  1.42 (0.87–2.30)  |
| Missing                 | 4/6 (66.7%)       1.64 (0.79–3.39)  | 3/6 (50.0%)       1.04 (0.42–2.54) |
| **Baseline CD4**        |                                |                                |
| ≤ 250 (n = 78)          | 39/78 (50.0%)     1.00                | 41/78 (52.6%)  1.00                |
| > 250 (n = 31)          | 16/31 (51.6%)     1.03 (0.69–1.55)  | 12/31 (38.7%)  0.74 (0.45–1.21) 0.82 (0.45–1.50) |
Table 4 Demographic and clinical factors associated with having a low MCS or PCS component summary score (Continued)

|                      | Mental component summary score | Physical component summary score |
|----------------------|--------------------------------|---------------------------------|
|                      | N, % (n = 74)                  | Crude RR (95% CI)               | Adjusted RR (95% CI) |
|                      | Crude RR (95% CI)               | Adjusted RR (95% CI)            |
|                      | N, % (n = 75)                  | Crude RR (95% CI)               | Adjusted RR (95% CI) |
|                      | Crude RR (95% CI)               | Adjusted RR (95% CI)            |
| CD4 count unknown (n = 7) | 4/7 (57.1%)                    | 1.14 (0.58–2.56)               | 6/7 (85.7%)          |
|                      |                               |                                 |                    |
|                      | Adjusted RR (95% CI)            |                                 | 1.63 (1.13–2.36)    |
|                      |                               |                                 |                    |
|                      | 1.04 (0.55–1.94)               |                                 |                    |
|                      | Indications for DR-TB regimen  |                                 |                    |
|                      | Standard regimen (long- or short-course) | 55/107 (51.4%) | 1.14 (0.78–1.66) | 1.49 (1.00–2.24) |
|                      | Individualized regimen (injection free) | 19/42 (45.2%) | 1.0          | 1.0          |
|                      | Duration of DR-TB treatment (months) | ≤ 6 months | 49/66 (74.2%) | 2.46 (1.72–3.53) | 2.27 (1.53–3.35) |
|                      | Hypoactive (n = 14) | 10/14 (71.4%) | 1.91 (1.21–3.02) | 1.46 (0.96–2.23) |
|                      | > 6 months | 25/83 (30.1%) | 1.0          | 1.0          |
|                      | Duration of ART (months) | ≤ 6 months | 31/83 (37.3%) | 1.0          | 1.0          |
|                      | Hypoactive (n = 14) | 10/13 (76.9%) | 2.06 (1.34–3.18) | 1.58 (0.96–2.59) |
|                      | > 6 months | 25/67 (31.3%) | 1.0          | 1.0          |
|                      | ART start date unknown (n = 13) | 10/13 (76.9%) | 1.91 (1.26–2.90) | 1.58 (0.96–2.60) |
|                      | Anaemia | None or mild (Hb ≥ 11.0 g/dL) | 29/64 (45.3%) | 1.00          | 31/64 (48.8%) |
|                      | Hypoactive (n = 14) | 14/26 (53.8%) | 1.19 (0.76–1.86) | 1.11 (0.72–1.72) |
|                      | > 6 months | 25/67 (31.3%) | 1.0          | 1.0          |
|                      | ART start date unknown (n = 13) | 31/59 (52.5%) | 1.16 (0.81–1.67) | 30/59 (50.8%) |
|                      | ≥ 50 kg | 17/37 (45.9%) | 0.91 (0.61–1.36) | 0.98 (0.67–1.44) |
|                      | > 6 months | 5/9 (55.6%) | 1.10 (0.59–2.04) | 1.35 (0.81–2.23) |
|                      | Weight at diagnosis (kg) | < 50 kg | 52/103 (50.5%) | 1.00          | 51/103 (49.5%) |
|                      | ≥ 50 kg | 17/37 (45.9%) | 0.91 (0.61–1.36) | 0.98 (0.67–1.44) |
|                      | Missing | 5/9 (55.6%) | 1.10 (0.59–2.04) | 1.35 (0.81–2.23) |
|                      | Referring Facility | Outpatient | 47/100 (47.0%) | 1.00          | 48/100 (48.0%) |
|                      | Hypoactive (n = 14) | 27/49 (55.1%) | 1.17 (0.84–1.63) | 1.15 (0.83–1.59) |
|                      | Inpatient | 14/23 (60.9%) | 1.17 (0.79–1.71) | 1.25 (0.87–1.79) |
|                      | Patient Category | New | 47/90 (52.2%) | 1.00          | 47/90 (52.2%) |
|                      | Hypoactive (n = 14) | 13/36 (36.1%) | 0.69 (0.43–1.12) | 0.69 (0.43–1.12) |
|                      | > 6 months | 14/23 (60.9%) | 1.17 (0.79–1.71) | 1.25 (0.87–1.79) |
|                      | TB Type | PTB and EPTB or EPTB only | 11/24 (45.8%) | 1.00          | 12/24 (45.8%) |
|                      | Hypoactive (n = 14) | 63/125 (50.4%) | 1.10 (0.69–1.76) | 1.01 (0.65–1.56) |
|                      | > 6 months | 63/125 (50.4%) | 1.10 (0.69–1.76) | 1.01 (0.65–1.56) |
|                      | Hypoactive (n = 14) | 13/36 (36.1%) | 0.69 (0.43–1.12) | 0.69 (0.43–1.12) |
|                      | > 6 months | 14/23 (60.9%) | 1.17 (0.79–1.71) | 1.25 (0.87–1.79) |
### Table 4 Demographic and clinical factors associated with having a low MCS or PCS component summary score (Continued)

| Smear Microscopy | Mental component summary score | Physical component summary score |
|------------------|--------------------------------|---------------------------------|
|                  | N, % (n = 74)                  | Crude RR (95% CI)               | Adjusted RR (95% CI) |
| Negative         | 49/99 (49.5%)                  | 1.00                            | 1.00                |
| Positive         | 10/26 (38.5%)                  | 0.78 (0.46–1.32)                | 1.26 (0.87–1.83)    |
| Missing          | 15/24 (62.5%)                  | 1.26 (0.87–1.83)                | 15/24 (62.5%)       | 1.29 (0.89–1.87) |

# Among patients who are HIV positive (n = 116)

& Among patients who are HIV positive and on ART (n = 94)

\* Standard long-course = 6 months of injectable kanamycin and 18–24 months of oral moxifloxacin, ethionamide, terizidone, and pyrazinamide

\+ Individualized long-course = bedaquiline was introduced as a substitute for kanamycin in the standard long-course regimen (either at start of DR-TB or switched during treatment due to an incident adverse event)

\- Standard short-course = 4 to 6-month intensive phase of kanamycin, moxifloxacin, ethionamide, clofazimine, pyrazinamide and high-dose isoniazid followed by 5 months of moxifloxacin, clofazimine, pyrazinamide and ethambutol

\d Individualized short-course = bedaquiline was introduced as a substitute for kanamycin in the standard short-course regimen (either at start of DR-TB or switched during treatment due to an incident adverse event)
also reveal the underlying driver of poor HRQoL. Untreated depression in patients with TB is associated with worse treatment outcomes, poor quality of life and greater disability [45]. Depression is often comorbid with TB and HIV and disproportionately affects those in lower socio-economic groups [46]. We note that a MCS lower than a PCS summary score must be interpreted with caution, however, as it may be an artefact of the way the summary scores are calculated [47]. Despite this, our results highlight the need to monitor mental health among DR-TB patients and provide support where possible. We recommend combining the SF-36 questionnaire with a screening tool for anxiety or psychological distress, such as the 10 item Kessler Psychological Distress Scale (K10) [48], throughout both the intensive and continuation phase of DR-TB treatment, to identify patients who require support or mental health care.

Study limitations
Results should be considered in light of the study limitations. First, because this was a cross-sectional study, one of the major limitations is temporality. Since risk factors and outcomes are measured simultaneously, it was impossible to make inferences about causality. Another limitation of cross-sectional studies is the potential introduction of survival bias: serious AEs (e.g. hearing loss) or AEs with longer duration are sometimes overrepresented because patients are more likely to be included in the sample and are more likely to present with and report the AE compared to those who recover quickly (e.g. mild or moderate AE) or who die before they can be interviewed. Similarly, patients with potentially life threatening AEs often require hospitalization and would therefore have been excluded.

Second, for the norm-based approach, the 2016 United States population mean and standard deviation were used to standardize the score. Data for a South African reference population were not available. The standard scoring algorithm assumes that MCS and PCS summary scores are not correlated, which can sometimes result in inconsistent results between the SF-36 domains and the MCS or PCS summary scores [47]. For these reasons, we opted to present the normal additive approach (not standardized), the norm-based approach (standardized) and the MCS and PCS summary scores.

Third, majority of the participants were HIV positive and only 18.1% were HIV negative therefore no inferences could be made between the two groups. Furthermore, the comparison patient groups were small and were only included for comparative purposes.

Finally, HRQoL and AE data relied on patient self-report. AEs were not graded by the treating clinician (e.g. as mild/grade 1, moderate/grade 2, severe/grade 3, potentially life-threatening/grade 4 or fatal/grade 5). No laboratory values or clinical records were reviewed and AEs that occurred before the 4 week cut-off were excluded (except those that were persistent or caused disability e.g. hearing loss). Patients may have over- or under-reported symptoms or AEs during an interview. Questionnaires were administered in English and verbally translated into local languages by interviewers so a poor understanding of the questions may have contributed to reporting bias. To overcome this, we used a checklist system to capture the adverse drug reaction and also used open-ended questions to ask patients if they were having any problems [49]. To minimize bias, the interviewer trained to administer the questionnaire was not a TB clinic nurse and did not provide TB or HIV care to these patients. Studies have demonstrated a discordance between patient and clinician reports of AEs to MDR-TB treatment with underreporting of patient adverse drug reactions in medical records [50]. In future work we plan to explore the concordance/discordance between patient-reported and clinician documentation of AEs in this sample.

Conclusion
Both DR-TB and HIV treatment pose the risk of AEs; concurrent treatment creates the potential for overlapping toxicities. Patients who reported an AE during DR-TB treatment experienced poorer HRQoL, affecting both their mental and physical health, than those who did not report an AE. We found that AEs contributed to poorer HRQoL during the first few months of treatment but diminished in impact on HRQoL as treatment continued. The availability of drugs with better safety profiles and management of patients that is more responsive (i.e. an integrative patient-centered approach) may result in improved HRQoL which will result in better treatment outcomes and contribute to global efforts to control TB [18].

Additional files

- **Additional file 1:** Table S1. Summary of approaches used to score the SF-36. (DOCX 16 kb)
- **Additional file 2:** Table S2. Summary of symptoms and associated adverse events related to DR-TB treatment. (DOCX 24 kb)
- **Additional file 3:** Table S3. Comparison of SF-36 health domain scales (norm-based) for healthy adults (n=40). (DOCX 15 kb)

Abbreviations
AE: Adverse event; aHR: Adjusted hazard ratio; aRR: Adjusted relative risk; ART: Antiretroviral therapy; BDQ: Bedaquiline; COJ: City of Johannesburg; DR: Drug resistant; DS: Drug susceptible; HIV: Human immunodeficiency virus; HREC: Human research ethics committee – medical; HRQoL: Health-related quality of life; IQR: Interquartile range; LPA: Line probe assay; MCS: Mental component summary score; MDR: Multi-drug resistant; MTB: Mycobacterium tuberculosis; NDOH: National Department of Health; NHL: National Health Laboratory Service; PCS: Physical component summary score; PTB: Pulmonary tuberculosis; RIF: Rifampicin; RMR: Rifampicin mono-resistant tuberculosis; RR-TB: Rifampicin-resistant tuberculosis; TB: Tuberculosis; USA: United States of
Acknowledgements
The authors wish to thank the staff at TB Focal Point, Thembha Lethu Clinic, Helen Joseph Hospital which is supported by the South African National and Gauteng Provincial Departments of Health. A special thank you to Elin Bankel and Sara Dahlberg from Sahlgrenska University Hospital who assisted with the pilot study.

Funding
This study has been made possible by the generous support of the American People and the President’s Emergency Plan for AIDS Relief (PEPFAR) through US Agency for International Development (USAID) under the terms of Cooperative Agreements AID-674-A-12-00029 and 72067419CA00004 to Health Economics and Epidemiology Research Office (DE, RB, TS, NM, LL) and under the terms of Cooperative Agreement 674-A-00-09-00018-00 to Boston University (LL, SR). The contents are the responsibility of the authors and do not necessarily reflect the views of PEPFAR, USAID or the United States Government. The funders had no role in the study design, collection, analysis and interpretation of the data, in manuscript preparation or the decision to publish.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available as the data are owned by the study site (i.e. Helen Joseph Hospital) and the National Department of Health (South Africa) and governed by the Human Research Ethics Committee (University of the Witwatersrand, Johannesburg, South Africa). All relevant data are included in the paper. The full data are available from the Health Economics and Epidemiology Research Office for researchers who meet the criteria for access to confidential data and with permission from the owners of the data.

Authors’ contributions
RB, KS, SR, DE, EL conceptualized and designed the study. RB, EL and DE developed the protocol and obtained relevant approvals. TS and NM were involved in study implementation, training interviewers, data collection and quality control. TS and DE analyzed the data and wrote the manuscript. KS, RB, EL, HvA, LL and SR assisted in interpreting the results and provided feedback on the manuscript. All authors critically reviewed and gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Ethics approval and consent to participate
This study was approved by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (Wits HREC M141188). All participants provided written informed consent to participate in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements
The authors wish to thank the staff at TB Focal Point, Thembha Lethu Clinic, Helen Joseph Hospital which is supported by the South African National and Gauteng Provincial Departments of Health. A special thank you to Elin Bankel and Sara Dahlberg from Sahlgrenska University Hospital who assisted with the pilot study.

Funding
This study has been made possible by the generous support of the American People and the President’s Emergency Plan for AIDS Relief (PEPFAR) through US Agency for International Development (USAID) under the terms of Cooperative Agreements AID-674-A-12-00029 and 72067419CA00004 to Health Economics and Epidemiology Research Office (DE, RB, TS, NM, LL) and under the terms of Cooperative Agreement 674-A-00-09-00018-00 to Boston University (LL, SR). The contents are the responsibility of the authors and do not necessarily reflect the views of PEPFAR, USAID or the United States Government. The funders had no role in the study design, collection, analysis and interpretation of the data, in manuscript preparation or the decision to publish.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available as the data are owned by the study site (i.e. Helen Joseph Hospital) and the National Department of Health (South Africa) and governed by the Human Research Ethics Committee (University of the Witwatersrand, Johannesburg, South Africa). All relevant data are included in the paper. The full data are available from the Health Economics and Epidemiology Research Office for researchers who meet the criteria for access to confidential data and with permission from the owners of the data. Contact the organization at information@heroza.org for additional information regarding data access.

Authors’ contributions
RB, KS, SR, DE, EL conceptualized and designed the study. RB, EL and DE developed the protocol and obtained relevant approvals. TS and NM were involved in study implementation, training interviewers, data collection and quality control. TS and DE analyzed the data and wrote the manuscript. KS, RB, EL, HvA, LL and SR assisted in interpreting the results and provided feedback on the manuscript. All authors critically reviewed and gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Ethics approval and consent to participate
This study was approved by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (Wits HREC M141188). All participants provided written informed consent to participate in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. World Health Organization. Global tuberculosis report 2018. Annex 2: country profiles. Geneva: World Health Organization; 2018. https://www.who.int/tb/publications/global_report/gbr2018_annex2pdf_en.pdf?ua=1. Accessed 08 March 2019
2. Dela AL, Tank ND, Singh AP, Pipana KG. Adverse drug reactions and treatment outcome analysis of DOTs-plus therapy of MDR-TB patients at district tuberculosis Centre: a four year retrospective study. Lung India. 2017;34(6):522.
3. Schnippel K, Berhanu RH, Black A, Finnhaber C, Matiisa N, Evans D, Sinanovic E. Severe adverse events during second-line tuberculosis treatment in the context of high HIV co-infection in South Africa: a retrospective cohort study. BMC Infect Dis. 2016;16:593.
4. Brust KC, Shah NS, van der Merwe TL, Bamber S, Ning Y, Heo M, Moll AP, Loveday M, Laloo UG, Friedland GH, et al. Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2013;62(4):436–40.
5. Sagwa E, Ruswa N, Musapa JP, Mantel-Teeuwisse AK. Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection. Drug Saf. 2013;36(11):1087–96.
6. Schnippel K, Finnhaber C, Berhanu R, Page-Shipp L, Sinanovic E. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(7):1871–9.
7. Bliss E, Kuksa L, Holtz TH, Reikstina V, Skripconoka V, Kammeerer S, Leimane V. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis. 2010;14(3):275–81.
8. Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, Vink K, Jaramillo E, Espinal MA. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTs-plus initiative. The international journal of tuberculosis and lung disease : the official journal of the International Union Against Tuberculosis and Lung Disease. 2008;12(11):1382–4.
9. Sagwa E, Mantel-Teeuwisse AK, Ruswa N, Musapa JP, Pal S, Dhilliwayo P, van Wyk B. The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia. Southern Med Review. 2012;2(5):13–6.
10. Brown J, Capocci S, Smith C, Morris S, Abubakar I, Lipman M. Health status and quality of life in tuberculosis. Int J Infect Dis. 2015;32:66–75.
11. Guo N, Marra CA, Marra F, Maoebi S, Elwood RK, Fitzgerald JM. Health state utilities in latent and active tuberculosis. Value Health. 2008;11(7):1154–61.
12. Guo N, Marra CA, Marra F. Measuring health-related quality of life in tuberculosis: a systematic review. Health Qual Life Outcomes. 2009;7:14.
13. Louw J, Pettetz K, Naidoo P, Majtree G, Mchunu G, Tutshana B. Quality of life among tuberculosis (TB), TB retreatment and/or TB-HIV co-infected primary public health care patients in three districts in South Africa, Health Qual Life Outcomes. 2012;10:77.
14. Muniyandi M, Rajeswari R, Balasubramanian R, Nirupa C, Gopi PG, Jeggarajamma K, Sheela F, Narayanan PR. Evaluation of post-treatment health-related quality of life (HRQOL) among tuberculosis patients. Int J Tuberc Lung Dis. 2007;11(8):887–92.
15. Sharma R, Yadav R, Sharma M, Saini V, Koushal V. Quality of life of multi drug resistant tuberculosis patients: a study of North India. Acta Medica Iranica. 2014;52(6):448–53.
16. Uchmanowicz B, Chudiak A, Mazur G. The influence of quality of life on the level of adherence to therapeutic recommendations among elderly hypertensive patients. Patient Preference Adherence. 2018;12:2593.
17. Grover GS, Takkar J. Recent advances in multi-drug-resistant tuberculosis and RNTCP. Indian J Community Med. 2008;33(4):219.
18. Kastien-Hilka T, Rosenkranz B, Sinanovic E, Bennett B, Schwenkglenks M. Health-related quality of life in South African patients with pulmonary tuberculosis. PLoS One. 2017;12(4):e0174605.
19. National Department of Health. Media Statement “New Bedaquiline data shows reduction in TB mortality cases” 18 June 2018. Available online http://www.tbonline.info/media/uploads/documents/new_bedaquiline_data_shows_reduction_in_tb_mortality_cases.pdf. Accessed 4 Dec 2018.
20. World Health Organization. Rapid communication: key changes to treatment of multidrug-and rifampicin-resistant tuberculosis (MDR/RR-TB).
23. National Department of Health Republic of South Africa: Multi-drug resistant tuberculosis: a policy framework on decentralised and deinstitutionalised management for South Africa. Pretoria: 2011. Available online https://www.tb.facts.org/wp-content/uploads/2018/06/SA-MDR-TB-Policy.pdf.

24. National Department of Health Republic of South Africa: Introduction of new drugs and drug regimens for the management of drug-resistant tuberculosis in South Africa: policy framework. Pretoria: version 1.1. approved: June 2015. Available online http://www.tbonline.info/media/uploads/documents/policy_framework_ver_20150608.pdf. Accessed 15 Nov 2018.

25. Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, Hughes J, Ferreira H, Pedanlam X, Romero R. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018;6(9):699–706.

26. World Health Organization: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization, 2015. Available online https://www.who.int/hiv/pub/guidelines/ARV2013/en/. Accessed 7 Dec 2018.

27. World Health Organization: Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. 2017. Available online https://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en/. Accessed 15 Nov 2018.

28. Hays RD, Shapiro MF. An overview of generic health-related quality of life measures for HIV research. Qual Life Res. 1992;1(2):91–7.

29. Stewart AL. Measuring functioning and well-being: the medical outcomes study approach. Duke University Press; 1992.

30. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

31. de Vries St, Mol PG, de Zeeuw D, Haaijer-Ruskamp FM, denig P. Development and initial validation of a patient-reported adverse drug event questionnaire. Drug Saf. 2013;36(9):765–77.

32. Brazer JE, Harper R, Jones NM, O’Catthain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: new outcome measures for primary care. BMJ (Clinical research ed). 1992;305(6846):160–4.

33. Ruta DA, Abdalla MJ, Garratt AM, Coutts A, Russell IT. SF 36 health survey questionnaire: I. Reliability in two patient based studies. Qual Health Care. (QHC). 1994;3(4):180–5.

34. Ventry IM, Weinstein BE. Identification of elderly people with hearing problems. Am J Speech Lang Hearing Assoc. 1983;25(7):37–42.

35. Harris PA, RT RT, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Informatics. 2009;42(2):377–81.

36. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. 2011. Available online https://www.who.int/nmh/indicators/haemoglobin/en/. Accessed 15 July 2018.

37. World Health Organization. Vitamin and mineral nutrition information system. WHO global database on vitamin a deficiency. 2011. Available online https://www.who.int/vmnis/vitamina/data/en/. Accessed 15 July 2018.

38. Hagiwara Y, Shiroiwa T, Shimozuma K, Kawahara T, Uemura Y, Watanabe T, Taira N, Fukuda T, Ohashi Y, Mukai H. Impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the SELECT BC study. Pharmacoeconomics. 2018;36(2):215–23.

39. Tachi T, Teramachi H, Tanaka K, Asano S, Otsawa T, Kawashima A, Yasuda M, Mizui T, Nakada T, Noguchi Y, et al. The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients. PLoS One. 2015;10(4):e0124169.

40. Petersen L, Rogers C. Aminoglycoside-induced hearing deficits – a review of cochlear ototoxicity. S Afr Fam Pract. 2015;57(2):77–82.

41. Denbaw A, Tesfaye M, Hailmichael Y, Negussu N, Daba S, Wogi A, Belachew T, Apers L, Colebunders R. Tuberculosis and HIV co-infection: its impact on quality of life. Health Qual Life Outcomes. 2009;7:105.

42. Basavaraj KH, Navya MA, Rashmi R. Quality of life in HIV/AIDS. Indian J Sexually Transmitted Dis AIDS. 2010;12(2):75–80.

43. Sagar EA, Mantel-Teeuwisse AK, Ruswa NC. Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study. J Pharmacol PRACT. 2014;7(1):14.

44. Dheda K, Cox H, Esmail A, Wasserman S, Chang KC, Lange C. Recent controversies about MDR and XDR-TB: global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Respiriology. 2018;23(1):36–45.

45. Ambaw F, Wayston R, Hanlon C, Medhin G, Alem A. Untreated depression and tuberculosis treatment outcomes, quality of life and disability. Ethiopia. Bull World Health Organ. 2018;96(4):243.

46. Lee E. Prevalence of depression among active TB and TB/HIV patients in Kisumu County. Independent Study Project(ISP) Collection. 2015;2152.

47. Fairvan SS, Cunningham WE, Hays RD. Correlated physical and mental health summary scores for the SF-36 and SF-12 health survey, VI. Health Qual Life Outcomes. 2005;3:54.

48. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, Walters EE, Zaslavsky AM. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychiatr. Med. 2002;32(6):959–76.

49. Allen EN, Mushii AK, Massawe IS, Vestergaard LS, Lemnge M, Staedke SG, Mehta U, Barnes KL, Chandler CL. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trials. BMC Med Res Methodol. 2013;13:140.

50. Kelly AM, Smith B, Luo Z, Given B, Wehnwein T, Master I, Farley JE. Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment. Int J Tuberc Lung Dis. 2016;20(4):442–7.